PharmaBlock Sciences (Nanjing), Inc., a global CRDMO company with a focus on cutting-edge chemistry and sustainable manufacturing, recently unveiled its new high potency API (HPAPI) GMP facility (OEB-5 and above) at the Zhejiang manufacturing site.
The state-of-the-art HPAPI GMP facility empowers PharmaBlock to provide comprehensive services, including process research and development (R&D) and kilo-scale production of HPAPIs and ADC toxins. Encompassing an expansive 1000 m2 area, the facility is equipped with versatile rigid isolators and reactors ranging from 20 L to 100 L. It is designed to handle potent compounds with an Occupational Exposure Limit (OEL) as low as 50 ng/m3 (OEB-5 and above). Complementing this GMP HPAPI facility, multiple workshops at PharmaBlock Zhejiang have the capability to manufacture OEB-4 compounds.
PharmaBlock is actively enhancing its capabilities to offer research, development, and manufacturing services for emerging modalities such as targeted protein degraders, peptides, oligonucleotides, and ADCs. This initiative provides partners with comprehensive and highly flexible solutions. In the ADC domain, the company is expanding its library of linker-payload intermediates and building blocks to support ADC drug R&D. Additionally, PharmaBlock offers ADC chemistry CMC services, including linker-payload synthesis and ADC conjugation. The company has successfully executed process development and kilogram-scale production for various innovative linkers and optimized payloads. The introduction of the new HPAPI GMP facility significantly bolsters PharmaBlock's capability to deliver ADC projects to its global partners.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!